

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

INSIDE INFORMATION

- (1) EXPECTED DELAY IN PUBLICATION OF 2022 AUDITED ANNUAL RESULTS;**
(2) PUBLICATION OF 2022 UNAUDITED ANNUAL RESULTS; AND
(3) DATE OF BOARD MEETING

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

(1) EXPECTED DELAY IN PUBLICATION OF 2022 AUDITED ANNUAL RESULTS

The board (the “**Board**”) of directors (the “**Director(s)**”) would like to inform the shareholders of the Company (“**Shareholders**”) and potential investors that, due to the restrictions in Mainland China as a result of the outbreak of COVID-19 pandemic, the audit procedures of the Group could not be completed as scheduled, which mainly include (i) the delay in obtaining certain confirmations from the banks and financial institutions due to the restrictions on logistics; and (ii) the delay in audit procedures which require on-site verification. As a result, the Company anticipates that it will be unable to publish the audited annual results of the Group for the year ended 31 March 2022 (the “**2022 Audited Annual Results**”) on or before 30 June 2022 in accordance with Rule 13.49(1) of the Listing Rules.

Upon completion of audit procedures, the Company will endeavour to publish the 2022 Audited Annual Results as agreed with the auditors of the Company (the “**Auditors**”) as soon as practicable. Based on information currently available to the Company, the Company expects that the 2022 Audited Annual Results will be published on or before 29 July 2022.

The Board wishes to further supplement that the Company has been using its best endeavours to assist the Auditors in completing the audit work. As at the date of this announcement, the Company is not aware of any key audit issue identified which needs to be brought to the attention of the Shareholders and the Stock Exchange.

(2) PUBLICATION OF 2022 UNAUDITED ANNUAL RESULTS

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and (2) of the Listing Rules, it must announce, so far as the information is available, results for the financial year based on the financial results which have yet to be agreed with the auditors.

In order to keep Shareholders and potential investors informed of the business and financial position of the Group, the Company expects to publish the unaudited annual results of the Group for the year ended 31 March 2022 (the “**2022 Unaudited Annual Results**”), which will be reviewed by the audit committee of the Company, on 30 June 2022.

(3) DATE OF BOARD MEETING

The Board further announces that a meeting of the Board will be held on Thursday, 30 June 2022 to consider and approve, among other matters, the 2022 Unaudited Annual Results.

A further meeting of the Board is expected to be held after completion of the audit for the purpose of, among others, (i) considering and approving the 2022 Audited Annual Results and its publication; and (ii) considering the payment of a final dividend, if any. The Company will make further announcement(s) in accordance with Rule 13.43 of the Listing Rules as and when appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Boill Healthcare Holdings Limited
Dai Dong Xing
Executive Director and Chairman

Hong Kong, 20 June 2022

As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.